PARIS (Reuters) – French healthcare company Sanofi has agreed to buy Austrian group Origimm Biotechnology in a move that Sanofi said would boost its vaccines business.
“The acquisition of Origimm further broadens our vaccines research and development pipeline with a first vaccine candidate against acne, a high medical need for millions of teenagers and adults,” said Thomas Triomphe, executive vice president andglobal head of Sanofi Pasteur, on Wednesday.
(Reporting by Sudip Kar-Gupta; Editing by Tom Hogue)
